Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2023
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung CancerTao Jiang, Qiqi Jin, Jiahao Wang, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.
Lancet (London, England)|March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in ChinaAnwen Xiong, Lei Wang, Jianhua Chen, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2022
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)Xinan Sheng, Dingwei Ye, Aiping Zhou, et al.
Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2023
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung CancerTao Jiang, Qiqi Jin, Jiahao Wang, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Advances in Therapy|September 4, 2024
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III StudyYing Cheng, Zhanyu Pan, Lin Wu, et al.
Lancet (London, England)|March 8, 2025
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in ChinaAnwen Xiong, Lei Wang, Jianhua Chen, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Nature Medicine|July 11, 2024
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trialYing Cheng, Jianhua Chen, Wei Zhang, et al.
Pageof 15